Fig. 2 Efficacy outcomes in cycle 1 in the overall phase (0–120 h), acute phase (0–24 h), and delayed phase (>24–120 h): a complete response and proportion of patients achieving secondary end points in cycle 1 of b no significant nausea and c no emesis